{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T08:02:33Z","timestamp":1649059353826},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Vascular Surgery"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1053\/j.semvascsurg.2005.05.004","type":"journal-article","created":{"date-parts":[[2005,9,16]],"date-time":"2005-09-16T13:55:09Z","timestamp":1126878909000},"page":"134-138","source":"Crossref","is-referenced-by-count":1,"title":["Long-Term Anticoagulation: The Prospects for Alternatives to Warfarin"],"prefix":"10.1053","volume":"18","author":[{"given":"Jack","family":"Ansell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl","key":"10.1053\/j.semvascsurg.2005.05.004_bib1","doi-asserted-by":"crossref","first-page":"429S","DOI":"10.1378\/chest.126.3_suppl.429S","article-title":"Antithrombotic therapy in atrial fibrillation","volume":"126","author":"Singer","year":"2004","journal-title":"Chest"},{"issue":"suppl","key":"10.1053\/j.semvascsurg.2005.05.004_bib2","doi-asserted-by":"crossref","first-page":"202S","DOI":"10.1378\/chest.126.3_suppl.204S","article-title":"The pharmacology and management of the vitamin K antagonists","volume":"126","author":"Ansell","year":"2004","journal-title":"Chest"},{"issue":"suppl","key":"10.1053\/j.semvascsurg.2005.05.004_bib3","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1023\/A:1013276601930","article-title":"Anticoagulation management as a risk factor for adverse events","volume":"5","author":"Ansell","year":"1998","journal-title":"J Thromb Thrombolys"},{"key":"10.1053\/j.semvascsurg.2005.05.004_bib4","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1538-7836.2004.00775.x","article-title":"International normalized ratios (INR)","volume":"2","author":"Poller","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2005.05.004_bib5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archinte.160.1.41","article-title":"Why do patients with atrial fibrillation not receive warfarin?","volume":"160","author":"Bungard","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.semvascsurg.2005.05.004_bib6","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1001\/archinte.1996.00440210043004","article-title":"National patterns of warfarin use in atrial fibrillation","volume":"156","author":"Stafford","year":"1996","journal-title":"Arch Intern Med"},{"issue":"suppl","key":"10.1053\/j.semvascsurg.2005.05.004_bib7","doi-asserted-by":"crossref","first-page":"188S","DOI":"10.1378\/chest.126.3_suppl.188S","article-title":"Heparin and low-molecular-weight heparin","volume":"126","author":"Hirsh","year":"2004","journal-title":"Chest"},{"key":"10.1053\/j.semvascsurg.2005.05.004_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1527-3466.2002.tb00081.x","article-title":"Fondaparinux, a synthetic pentasaccharide","volume":"20","author":"Bauer","year":"2002","journal-title":"Cardiovascular Drug Reviews"},{"key":"10.1053\/j.semvascsurg.2005.05.004_bib9","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1001\/archinte.162.16.1833","article-title":"Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery","volume":"162","author":"Turpie","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.semvascsurg.2005.05.004_bib10","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","article-title":"Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis","volume":"140","author":"Buller","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.semvascsurg.2005.05.004_bib11","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2005.05.004_bib12","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1182\/blood.V91.11.4197","article-title":"Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide","volume":"91","author":"Herbert","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.semvascsurg.2005.05.004_bib13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1538-7836.2003.00516.x","article-title":"A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase 2 evaluation","volume":"2","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2005.05.004_bib14","first-page":"15a","article-title":"Phase II randomized, double-blind, five-arm, parallel-group, dose-response study of a new oral directly acting factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery","volume":"103","author":"Lassen","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.semvascsurg.2005.05.004_bib15","first-page":"811a","article-title":"Multiple dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY59-7939 an oral, direct factor Xa inhibitor in healthy male subjects","volume":"102","author":"Kubitza","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.semvascsurg.2005.05.004_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00228-003-0565-7","article-title":"Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects","volume":"59","author":"Eriksson","year":"2003","journal-title":"Eur J Clin Pharmaco"},{"key":"10.1053\/j.semvascsurg.2005.05.004_bib17","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jama.293.6.681","article-title":"Ximelagatran vs low molecular weight heparin and warfarin for the treatment of deep vein thrombosis","volume":"293","author":"Fiessinger","year":"2005","journal-title":"JAMA"},{"key":"10.1053\/j.semvascsurg.2005.05.004_bib18","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa030104","article-title":"Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran","volume":"349","author":"Schulman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2005.05.004_bib19","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","article-title":"Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation","volume":"362","year":"2003","journal-title":"Lancet"},{"key":"10.1053\/j.semvascsurg.2005.05.004_bib20","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jama.293.6.690","article-title":"Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation","volume":"293","year":"2005","journal-title":"JAMA"},{"key":"10.1053\/j.semvascsurg.2005.05.004_bib21","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","article-title":"Oral ximelagatran for secondary prophylaxis after myocardial infarction","volume":"362","author":"Wallentin","year":"2003","journal-title":"Lancet"},{"key":"10.1053\/j.semvascsurg.2005.05.004_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1538-7836.2004.01100.x","article-title":"A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement","volume":"3","author":"Erikson","year":"2005","journal-title":"J Thromb Haemost"}],"container-title":["Seminars in Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895796705000244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895796705000244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T15:08:45Z","timestamp":1586444925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895796705000244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["S0895796705000244"],"URL":"https:\/\/doi.org\/10.1053\/j.semvascsurg.2005.05.004","relation":{},"ISSN":["0895-7967"],"issn-type":[{"value":"0895-7967","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}